Steven Deeks, MD
Biography
Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment. He is also now leading a large program focused on the pathogenesis and treatment of Long COVID.
Dr. Deeks has published over 650 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants and is the contact principal investigator of DARE (the Delaney AIDS Research Enterprise), an NIH-funded international collaboration aimed at developing therapeutic interventions to cure HIV infection. He recently directed the amfAR Institute for HIV Cure Research. In early 2020, he leveraged his HIV research program to construct the “Long-term Impact of Infection with Novel Coronavirus (LIINC)” cohort, which is now supporting dozens of studies addressing the impact of SARS-CoV-2 on health.
Dr. Deeks is a member of the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP). He serves on the scientific advisory board for Science Translational Medicine and is the editor-in-chief of Current Opinion in HIV and AIDS. Based on a recent study conducted at Stanford, he is among the top 0.01% of all scientists, based on citations, adjusted for authorship position and impact, and has been listed by Clarivite as one of the world's most cited scientists for the past several years. In 2022, he received the Lifetime Achievement in Mentoring Award from UCSF.
In addition to his translational and clinical. investigation, Dr. Deeks maintains a primary care clinic for people living with HIV.
Displaying 651 - 668 of 668
- Deeks SG, Sax PE. Should we argue with success? AIDS Clin Care. 1998 Sep; 10(9):68, 72.
- Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS. 1998 Jul 09; 12(10):F97-102.
- Volberding PA, Deeks SG. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998 May 06; 279(17):1343-4.
- Deeks SG. Antiretroviral agents: the next generation. AIDS Clin Care. 1998 May; 10(5):33-6, 39-40.
- Follansbee S, Deeks S, Bartnoff H. Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker. Newsline People AIDS Coalit N Y. 1998 Mar; 7-14.
- Deeks S. Clinical implications of virological "failure": interview with Steven Deeks, M.D., San Francisco General Hospital. Interview by John S. James. AIDS Treat News. 1998 Feb 20; (No 289):1-6.
- Deeks SG. Practical issues regarding the use of antiretroviral therapy for HIV infection. West J Med. 1998 Feb; 168(2):133-9.
- Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, Jaffe HS, Mulato AS, Lamy PD, Li W, Cherrington JM, Hellmann N, Kahn J. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 1997 Dec; 176(6):1517-23.
- Deeks S, Kertesz D, Ryan A, Johnson W, Ashton F. Surveillance of invasive meningococcal disease in Canada, 1995-1996. Can Commun Dis Rep. 1997 Aug 15; 23(16):121-5.
- Deeks SG, Coleman RL, White R, Pachl C, Schambelan M, Chernoff DN, Feinberg MB. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J Infect Dis. 1997 Aug; 176(2):514-7.
- Deeks SG, Abrams DI. Genotypic-resistance assays and antiretroviral therapy. Lancet. 1997 May 24; 349(9064):1489-90.
- Deeks SG. New principles of HIV-related medical care. Focus. 1997 Apr; 12(5):5-7.
- Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997 Jan 08; 277(2):145-53.
- Gordon M, Deeks S, De Marzo C, Goodgame J, Guralnik M, Lang W, Mimura T, Pearce D, Kaneko Y. Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. J Med. 1997; 28(1-2):108-28.
- Deeks SG, Volberding PA. HIV-1 protease inhibitors. AIDS Clin Rev. 1997-1998; 145-85.
- Eron JJ, Ashby MA, Giordano MF, Chernow M, Reiter WM, Deeks SG, Lavelle JP, Conant MA, Yangco BG, Pate PG, Torres RA, Mitsuyasu RT, Twaddell T. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet. 1996 Dec 07; 348(9041):1547-51.
- Deeks S, Volberding P. An approach to antiretroviral treatment of HIV disease. Combined antiretroviral therapy: the emerging role. Hosp Pract (1995). 1995 Aug; 30 Suppl 1:23-31.
- Deeks S, Richards J, Nandi S. Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. Exp Cell Res. 1988 Feb; 174(2):448-60.